Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-08-13Clinical Trial Update: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 [Phase 2]
Phase 2 trial evaluating cabozantinib in adults with advanced, low-proliferative neuroendocrine neoplasms (NET G3), including neuroendocrine…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma [Phase 4]
Phase 4 trial evaluating liposomal irinotecan for neuroendocrine tumors. The study is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating ZG005 in combination with etoposide and cisplatin for advanced neuroendocrine carcinoma. The study…
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients [Phase 2]
A Phase 2 clinical trial evaluating simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG PET/MRS in cancer patients is currently enrollin…
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Clinical trial update on a multiparametric prognostic and predictive system to classify patients with neuroendocrine neoplasms grade 3 (NET …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC
This clinical trial update investigates prognostic and predictive factors in unresectable locally advanced neuroendocrine carcinoma (NEC) an…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors [Phase 2]
Phase II trial of pembrolizumab plus lenvatinib in advanced well-differentiated neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma [Phase 3]
Phase 3 trial evaluating surufatinib plus toripalimab for advanced neuroendocrine carcinoma is underway, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.
-
CLINICAL_TRIALS trial_result · 2023-05-30Clinical Trial Update: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin [Phase 2]
Phase 2 trial investigating everolimus as maintenance therapy for metastatic neuroendocrine carcinoma of pulmonary or gastroenteropancreatic…
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma [Phase 2]
Phase 2 clinical trial evaluating a regimen of paclitaxel, carboplatin, and oral etoposide followed by weekly paclitaxel in high-grade neuro…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. [Phase 1, Phase 2]
A single-arm, open-label clinical trial evaluating surufatinib combined with serplulimab, platinum, and etoposide in neuroendocrine carcinom…
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial update for TEMCAP in grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy [Phase 2]
Phase 2 trial evaluating surufatinib plus sintilimab in metastatic neuroendocrine tumors and pancreatic carcinoma after failure of standard …
-
CLINICAL_TRIALS trial_result · 2022-04-12Clinical Trial Update: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers [Phase 1, Phase 2]
A Phase 1/2 trial update reports completed results for combining topotecan with the ATR inhibitor berzosertib (VX-970/M6620) in small cell c…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy [Phase 2]
Phase 2 trial evaluating avelumab in neuroendocrine carcinomas grade 3 after chemotherapy has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers [Phase 1, Phase 2]
Phase 1/2 trial update for PEN-221 in somatostatin receptor 2 expressing advanced cancers, including neuroendocrine tumors and small cell lu…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm [Phase 2]
Phase 2 trial evaluating chidamide plus sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm; status not yet de…
-
CLINICAL_TRIALS trial_result · 2021-11-03Clinical Trial Update: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial evaluating chidamide with etoposide and cisplatin/carboplatin as first-line therapy for extrapulmonary neuroendocrine carcinom…
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study [Phase 2]
A Phase II investigator-initiated trial evaluating safety and tolerability of everolimus as second-line therapy in poorly differentiated neu…
-
CLINICAL_TRIALS trial_result · 2020-10-26Clinical Trial Update: Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas [Phase 2]
A Phase 2 clinical trial evaluating temozolomide as second-line treatment for neuroendocrine carcinomas has completed.
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery [Phase 2]
Phase 2 trial evaluating mutation-targeted therapy with sunitinib or everolimus in advanced low- or intermediate-grade neuroendocrine tumors…
-
CLINICAL_TRIALS trial_result · 2020-03-18Clinical Trial Update: Avelumab in G3 NEC [Phase 1, Phase 2]
Clinical trial update on avelumab in neuroendocrine carcinoma across Phase 1 and Phase 2 stages. The study is completed.
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial investigating pembrolizumab for recurrent high-grade neuroendocrine carcinoma (neuroendocrine tumors) has been terminated with…
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes [Phase 2]
Phase II study of avelumab as second-line treatment for metastatic gastroenteropancreatic neuroendocrine carcinoma (WHO Grade 3) afteretopos…